MidWest Drug Development Conference
Downtown Capitol District, Omaha, Neb. | Oct. 4-5, 2021
2021-10-04 08:00:00
Register!
Downloads
  • Map & Other Info (Coming soon!)
  • Brochure (Coming soon!)
  • Flyer (Coming soon!)
  • 2021 Program (Coming soon!)
  • 2019 Program
  • 2018 Program
  • Home
  • Schedule
  • Venue
  • Technologies
    • Technologies
    • Institutions
    • Startups
    • Previous Technologies
  • Sponsors
  • News
  • Contact
  • Home
  • Schedule
  • Venue
  • Technologies
    • Technologies
    • Institutions
    • Startups
    • Previous Technologies
  • Sponsors
  • News
  • Contact

Agmatine-based pain treatment avoids opioid addiction

University of Minnesota

The search for better analgesics has focused on non-addictive alternatives. Agmatine, the decarboxylated product of arginine, is a potential candidate for novel therapeutics.

Currently, over 100 million adults in the United States experience chronic pain, highlighting a significant clinical need. However, there are limited options for safe and efficacious treatments for patients experiencing chronic pain despite years of research on different therapeutics. Opioids are the gold standard treatment for chronic pain, but these medications have significant addiction and tolerance side effects associated with the exploding opioid abuse epidemic. Together there is need for new interventions with superior analgesic properties and limited undesirable side effects.

Agmatine has previously been shown to reduce chronic pain and block opioid tolerance and dependence. However, agmatine is a highly polar molecule and thus is not conducive to delivery across the blood brain barrier itself. Therefore, the current technology aims to deliver strategically substituted agmatine (SSA) molecules systemically that can cross the blood brain barrier more readily and allow for chronic pain reduction.

Based on compelling pre-clinical data, these SSAs could be used in cases of neuropathic pain, opioid addiction and opioid analgesic tolerance.

Features/Benefits

  • Non-addictive: Blocks opioid tolerance and dependence.
  • Reverses chronic pain: Decreases pain associated with inflammation and nerve injury.
  • Permeates the blood-brain barrier and readily achieves a potent analgesic effect.

Applications

  • Inflammatory pain
  • Neuropathic pain
  • Spinal cord injury

Logo

MIDWEST DRUG DEVELOPMENT CONFERENCE
Bringing together industry and the best university drug development researchers in the Midwest
Downtown Capitol District, Omaha, NE
Oct. 4-5, 2021

Latest News
  • Registrations are now open for 2021 March 25, 2021
  • Planners set initial slate of participants, more to come February 22, 2021
  • MidWest Drug Development Conference plans to return in 2021 January 11, 2021
  • MidWest Drug Development Conference for 2020 is postponed July 15, 2020
Twitter Hightlights
  • 👀 https://t.co/WWaZ16hOhr https://t.co/XErdmyAequ
    5 days ago
  • RT @SharpIdeaHub: Drive change in the world with your research - Attend ABC of #SBIR/#STTR #Funding on April 21 at 8:30 am CST Register: ht…
    6 days ago